Showing 331-340 of 1741 results for "".
- Vascular Health and Treating Migrainehttps://practicalneurology.com/news/vascular-health-and-treating-migraine/2469440/As new migraine treatments have become available that do not have cardiovascular contraindications, many questions have arisen regarding whether a new therapy—lasmiditan—is truly safe for those with cardiovascular risk. These important considerations for the 12% of peo
- Muscular Dystrophy Association Launches Data Reporting and Visualization Platform for Neuromuscular Diseasehttps://practicalneurology.com/news/muscular-dystrophy-association-launches-data-reporting-and-visualization-platform-for-neuromuscular-disease/2469411/The Muscular Dystrophy Association (MDA) has announced the availability of its new data sharing platform, the neuromuscular observational research (MOVR) visualization and reporting platform (VRP). MOVR-VRP represents a milestone in advancing neuromuscular disease research and improving patient c
- FDA Approves Expanded use of Pitolisant for Treatment of Cataplexy in Adults With Narcolepsyhttps://practicalneurology.com/news/fda-approves-expanded-use-of-pitolisant-for-treatment-of-cataplexy-in-adults-with-narcolepsy/2469405/The Food and Drug Administration (FDA) approved pitolisant (Wakix; Harmony Biosciences Plymouth Meeting, PA)—treatment of cataplexy in adults with narcolepsy. Pitolisant is the first and only treatment not categorized as a controlled substance that is approved by the FDA for treating sympto
- High-Dose Biotin Did Not Improve Disability for Individuals With Active Secondary Progressive MS in Phase 3 Trialhttps://practicalneurology.com/news/high-dose-biotin-did-not-improve-disability-for-individuals-with-active-secondary-progressive-ms-in-phase-3-trial/2469189/The second pivotal phase 3 trial (SPI2) (NCT02936037) of investigational high-dose biotin (MD1003, MedDay Pharmaceuticals, Boston, MA) did not improve disability for individuals with active secondary p
- FDA Authorizes First Test to Aid in Newborn Screening for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-authorizes-first-test-to-aid-in-newborn-screening-for-duchenne-muscular-dystrophy/2469111/The Food and Drug Administration (FDA) has authorized marketing of the 1st test to aid in newborn screening for Duchenne Muscular Dystrophy (DMD). The test (GSP Neonatal Creatine Kinase—MM; PerkinElmer, Inc., Waltham, MA) works by measuring the concentration of the CK-MM protein, which is p
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Clinical Trial of Rimegepant for Trigeminal Neuralgia Enrolls First Participanthttps://practicalneurology.com/news/clinical-trial-of-rimegepant-for-trigeminal-neuralgia-enrolls-first-participant/2468946/The first patient has been enrolled in a double-blind placebo-controlled clinical trial (NCT03941834) to assess rimegepant (Biohaven Pharmaceuticals, New Haven, CT)—a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist—for treatment of trigeminal neuralgia refrac
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent
- Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and IIIhttps://practicalneurology.com/news/nusinersen-efficacy-for-later-onset-spinal-muscular-atrophy-types-ii-and-iii/2468883/April 24, 2019—Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvement and disease stabilization over a 3-year period. Of the children with SMA II, 78% (7 of 9) had clinically meaningful
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in